• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Up­dat­ed: En­do and Mallinck­rodt to merge in $6.7B deal

2 months ago
Deals

Mallinck­rodt and En­do ex­plor­ing a $7B merg­er — re­port

2 months ago
Deals

Re­searchers make case against Gilead in HIV prod­uct hop­ping fight

2 months ago
Pharma
Law

#CROI25: Mer­ck’s trou­bled HIV drug heads to reg­u­la­tors; Vi­iV seeks longer-act­ing HIV treat­ment

2 months ago
R&D

As­cle­tis’ not-so-great weight loss da­ta; Vi­vace’s $35M Se­ries D

2 months ago
News Briefing

In­sil­i­co nabs $110M Se­ries E for AI drug dis­cov­ery af­ter stalling Hong Kong IPO plans

2 months ago
Financing
Startups

Viking Ther­a­peu­tics taps Cor­den­Phar­ma to man­u­fac­ture its obe­si­ty drugs

2 months ago
Pharma
Manufacturing

Leg­end to dou­ble Carvyk­ti pro­duc­tion as it tar­gets block­buster sta­tus 

2 months ago
Pharma
Cell/Gene Tx

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

2 months ago
Deals
R&D

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

2 months ago
Deals
R&D

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

2 months ago
People
FDA+

Mer­ck scores a win in Gar­dasil cas­es af­ter judge says plain­tiffs’ ev­i­dence ‘falls far short’

2 months ago
Pharma
Law

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

2 months ago
R&D

Wal­greens turns on dark mode

2 months ago
Health Tech

Cor­rect­ed: Min­eralys aims to raise $250M; Co­herus' staffing changes

2 months ago
News Briefing

En­do sells in­ter­na­tion­al busi­ness for $84M

2 months ago
Deals

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

2 months ago
Pharma
Manufacturing

Ex­clu­sive: De­fine Ven­tures hires for­mer Ae­tion CEO Car­olyn Mag­ill

2 months ago
People
Health Tech

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

2 months ago
R&D

Bris­tol My­ers buys out cell ther­a­py part­ner 2sev­en­ty bio

2 months ago
Deals
Pharma

Vir­tu­al phys­i­cal ther­a­py start­up Hinge Health files to go pub­lic

2 months ago
Health Tech

New Flag­ship start­up aims to trail­blaze ‘AI sci­ence fac­to­ries’

2 months ago
Startups
AI

BioN­Tech's shares dip af­ter post­ing luke­warm rev­enue guid­ance

2 months ago
Pharma

Com­pounders’ mo­tion for pre­lim­i­nary in­junc­tion de­nied in case over tirzepatide short­age

2 months ago
Pharma
Law
First page Previous page 30313233343536 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News